Table 1.
Groups (n=6) | Dose (mg/kg) | Inhibition percentage (%) | |
---|---|---|---|
Acute phase | Chronic phase | ||
Total extract | 50 | 38.03±5.2 **** | 6.21±4.29 #### |
100 | 46.83±3.59 *** | 10.83±8.85 #### | |
200 | 45.03±6.17 **** | 17.58±7.55 #### | |
n-Hexane fraction | 50 | 1.85±6.71 #### | 66.78±3.05 **** |
100 | 9.98±12.07 ### | 75.37±7.26 **** | |
200 | 23.02±13.10 | 79.92±6.12 **** | |
Residual fraction | 50 | 9.4±15.2 ### | 75.07±8.67 **** |
100 | 23.5±12.65 | 80.10±9.11 **** | |
200 | 25.63±14.22 | 80.63±4.02 **** | |
Morphine | 5 | 39.99±3.25 | 71.58±2.98 |
Different doses of all extracts were administered intraperitoneally to mice, 30 min before intraplantar injection of formalin. Antinociception was recorded 0-5 min (acute phase) and 15-60 min (chronic phase) after formalin injection. Values are mean±S.D. for each group of six mice.
p<0.05,
p<0.01,
p<0.001,
p<0.0001 (as compared to acute or chronic phase),
p<0.05,
p<0.01,
p<0.001
p<0.0001 (as compared to morphine 5 mg/kg).